{"clinical_study": {"@rank": "224", "required_header": {"download_date": "ClinicalTrials.gov processed this data on April 03, 2020", "link_text": "Link to the current ClinicalTrials.gov record.", "url": "https://clinicaltrials.gov/show/NCT04332094"}, "id_info": {"org_study_id": "IIBSP-COV-2020-23", "nct_id": "NCT04332094"}, "brief_title": "Clinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of COVID-19", "acronym": "TOCOVID", "official_title": "Pilot, Randomized, Multicenter, Open-label Clinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of SARS-CoV-2 Infection (COVID-19)", "sponsors": {"lead_sponsor": {"agency": "Fundaci\u00f3 Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau", "agency_class": "Other"}, "collaborator": {"agency": "Instituto de Salud Carlos III", "agency_class": "Other"}}, "source": "Fundaci\u00f3 Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau", "oversight_info": {"has_dmc": "No", "is_fda_regulated_drug": "No", "is_fda_regulated_device": "No"}, "brief_summary": {"textblock": "COVID-19 is a respiratory disease caused by the new coronavirus (SARS-CoV-2) and causes\n      considerable morbidity and mortality.\n\n      Currently, there is no vaccine or therapeutic agent to prevent and treat a SARS-CoV-2\n      infection. This clinical trial is designed to evaluate the use of Tocilizumab in combination\n      with hydroxychloroquine and azithromycin for the treatment of hospitalized adult patients\n      with COVID-19."}, "overall_status": "Not yet recruiting", "start_date": {"@type": "Anticipated", "#text": "April 2020"}, "completion_date": {"@type": "Anticipated", "#text": "October 2020"}, "primary_completion_date": {"@type": "Anticipated", "#text": "September 2020"}, "phase": "Phase 2", "study_type": "Interventional", "has_expanded_access": "No", "study_design_info": {"allocation": "Randomized", "intervention_model": "Parallel Assignment", "primary_purpose": "Treatment", "masking": "None (Open Label)"}, "primary_outcome": [{"measure": "In-hospital mortality", "time_frame": "Through hospitalization, an average of 2 weeks"}, {"measure": "Need for mechanical ventilation in the Intensive Care Unit", "time_frame": "Through hospitalization, an average of 2 weeks"}], "number_of_arms": "2", "enrollment": {"@type": "Anticipated", "#text": "276"}, "condition": "COVID", "arm_group": [{"arm_group_label": "Intervention", "arm_group_type": "Experimental", "description": "Early administration of tocilizumab associated with hydroxychloroquine and azithromycin."}, {"arm_group_label": "Control", "arm_group_type": "Active Comparator", "description": "Treatment of SARS-COV-2 (COVID-19) infection with hydroxychloroquine and azithromycin."}], "intervention": [{"intervention_type": "Drug", "intervention_name": "Tocilizumab", "description": "162 mg sc x 2 doses + tocilizumab 162mg sc x 2 doses at 12 hours (day 1)", "arm_group_label": "Intervention"}, {"intervention_type": "Drug", "intervention_name": "Hydroxychloroquine", "description": "400 mg / 12h v.o. day 1 followed by 200 mg / 12h v.o. for 6 days (7 days in total)", "arm_group_label": ["Control", "Intervention"]}, {"intervention_type": "Drug", "intervention_name": "Azithromycin", "description": "500 mg / day v.o. for 3 days", "arm_group_label": ["Control", "Intervention"]}], "eligibility": {"criteria": {"textblock": "Inclusion Criteria:\n\n          -  Subject (or authorized legal representative) who can provide written informed consent\n             before beginning any study procedure.\n\n          -  Understand and agree to abide by the study procedures.\n\n          -  Adult #18 years of age at the time of inclusion in the study.\n\n          -  Confirmation of SARS-CoV-2 infection by a microbiological test performed before\n             randomization, no longer than 72 hours.\n\n          -  Severity 3-4 according to the WHO 7-point ordinal scale.\n\n        Exclusion Criteria:\n\n          -  ALT / AST> 5 times the normal limit\n\n          -  Stage 4 chronic kidney disease (GFR <30) or requiring dialysis.\n\n          -  Presence of comorbidities that imply a poor prognosis (according to clinical\n             judgment).\n\n          -  Advanced dementia.\n\n          -  Pregnancy or breastfeeding.\n\n          -  Anticipation of transfer to another center in the 12 hours at the beginning of the\n             study.\n\n          -  Allergy to study medication.\n\n          -  Serious or active bacterial infections or documented sepsis by pathogens other than\n             SARS-CoV-2.\n\n          -  Streptococcus pneumoniae antigenuria positive before study start.\n\n          -  Neutropenia <500 / mm3.\n\n          -  Thrombocytopenia <100,000 / mm3.\n\n          -  History of diverticulosis.\n\n          -  Ongoing skin infection (eg, pyodermitis).\n\n          -  Transplanted patient under immunosuppressive treatment.\n\n          -  Previous evidence of latent untreated tuberculosis."}, "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No"}, "overall_contact": {"last_name": "Pere Domingo, MD, PhD", "email": "pdomingo@santpau.cat"}, "verification_date": "April 2020", "study_first_submitted": "March 31, 2020", "study_first_submitted_qc": "April 1, 2020", "study_first_posted": {"@type": "Actual", "#text": "April 2, 2020"}, "last_update_submitted": "April 1, 2020", "last_update_submitted_qc": "April 1, 2020", "last_update_posted": {"@type": "Estimate", "#text": "April 3, 2020"}, "responsible_party": {"responsible_party_type": "Sponsor"}, "intervention_browse": {"mesh_term": "Hydroxychloroquine"}}}